Sign inJoin waitlistJoin the waitlist

Charles Geyer

Hematology & Oncology · University of Pittsburgh Physicians

Credentials: · · · ·

History

UPMC Medical Education
1983–1986
Internal Medicine
1980–1983
Texas Tech University Health Sciences Center School of Medicine
1976–1980

Research

Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer
New England Journal of Medicine · 2005 · 4,152 citations
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
Review · The Lancet · 2014 · 3,800 citations
Lapatinib plus capecitabine for HER2-positive advanced breast cancer
New England Journal of Medicine · 2006 · First of 18 authors · Corresponding · 2,590 citations

Norman Wolmark
84 papers
EM
Eleftherios Mamounas
62 papers
Priya Rastogi
59 papers
SS
Sandra Swain
42 papers
LF
Louis Fehrenbacher
28 papers
AB
Adam Brufsky
27 papers
DW
Donald Wickerham
20 papers
SM
Silvana Martino
14 papers
EP
Edith Perez
12 papers
JA
James Atkins
11 papers
JP
Jonathan Polikoff
10 papers
Matthew Goetz
10 papers

Grants

VCU Massey Comprehensive Cancer Center NCI Community Oncology Research Program
National Cancer Institute · UG1
Contact PI · $3.8M · Virginia Commonwealth University
2014–2019

Clinical trials

Testing the Drug Atezolizumab or Placebo With Usual Therapy in First-Line HER2-Positive Metastatic Breast Cancer
Principal investigator · Terminated · Phase 3
National Cancer Institute (NCI)
2019–2025
Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
Principal investigator · Active not recruiting · Phase 3
AstraZeneca
2014–2029